Daily Respiratory Research Analysis
Three impactful respiratory studies stood out today: a phase 3, double‑blind active‑controlled trial shows once‑daily vanzacaftor‑tezacaftor‑deutivacaftor is non‑inferior to elexacaftor‑tezacaftor‑ivacaftor in cystic fibrosis, a large single‑cell atlas maps immune programs across mild and severe bacterial pneumonia, and a mechanistic study identifies splenic erythroblast‑like Ter‑cells that release artemin to curb acute lung injury progression.
Summary
Three impactful respiratory studies stood out today: a phase 3, double‑blind active‑controlled trial shows once‑daily vanzacaftor‑tezacaftor‑deutivacaftor is non‑inferior to elexacaftor‑tezacaftor‑ivacaftor in cystic fibrosis, a large single‑cell atlas maps immune programs across mild and severe bacterial pneumonia, and a mechanistic study identifies splenic erythroblast‑like Ter‑cells that release artemin to curb acute lung injury progression.
Research Themes
- Precision therapy in cystic fibrosis
- Immune heterogeneity in bacterial pneumonia
- Novel cellular mechanisms limiting acute lung injury
Selected Articles
1. A pan-immune panorama of bacterial pneumonia revealed by a large-scale single-cell transcriptome atlas.
Using scRNA-seq of 444k BALF cells from 74 participants, the study maps immune circuits across disease severities in bacterial pneumonia. Severe disease is dominated by S100A8/A9 and CXCL8 programs from specific macrophage and neutrophil subsets, whereas mild disease shows Tfh/Th2 expansion supporting humoral responses; T-cell exhaustion occurs in both, but cytotoxic CD8+ T cells are better preserved in mild cases.
Impact: Provides a reference single-cell atlas and actionable cytokine axes (S100A8/A9, CXCL8) linked to severity, enabling biomarker development and targeted immunomodulation trials.
Clinical Implications: Severity stratification could incorporate S100A8/A9 and CXCL8 measurements; therapies dampening these pathways or boosting humoral responses may benefit selected subsets.
Key Findings
- Severe bacterial pneumonia featured systemic upregulation of S100A8/A9 and CXCL8 from distinct macrophage and neutrophil subsets.
- Mild disease showed expansion of Tfh and Th2 cells, promoting B-cell activation and antibody production.
- T-cell exhaustion was present in both severities, with better preservation of cytotoxic CD8+ T cells in mild cases.
- Findings were validated by ELISA and histology within the same cohort.
Methodological Strengths
- Large-scale scRNA-seq of 444,146 BALF cells across 74 individuals spanning mild and severe disease plus healthy donors
- Orthogonal validation with ELISA and histology within the cohort
Limitations
- Observational, cross-sectional design limits causal inference
- BALF sampling may not capture tissue-resident programs or systemic compartments
Future Directions: Prospective studies to test S100A8/A9 or CXCL8 pathway inhibitors and to evaluate biomarker-driven stratification for adjunctive immunomodulation in bacterial pneumonia.
Bacterial pneumonia is a significant public health burden, contributing to substantial morbidity, mortality, and healthcare costs. Current therapeutic strategies beyond antibiotics and adjuvant therapies are limited, highlighting the need for a deeper understanding of the disease pathogenesis. Here, we employed single-cell RNA sequencing of 444,146 bronchoalveolar lavage fluid cells (BALFs) from a large cohort of 74 individuals, including 58 patients with mild (n = 22) and severe (n = 36) diseases as well as 16 healthy donors. Enzyme-linked immunosorbent and histological assays were applied for validation within this cohort. The heterogeneity of immune responses in bacterial pneumonia was observed, with distinct immune cell profiles related to disease severity. Severe bacterial pneumonia was marked by an inflammatory cytokine storm resulting from systemic upregulation of S100A8/A9 and CXCL8, primarily due to specific macrophage and neutrophil subsets. In contrast, mild bacterial pneumonia exhibits an effective humoral immune response characterized by the expansion of T follicular helper and T helper 2 cells, facilitating B cell activation and antibody production. Although both disease groups display T cell exhaustion, mild cases maintained robust cytotoxic CD8
2. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Across two double-blind, active‑controlled phase 3 trials (n=398 and n=573 randomized), once‑daily vanzacaftor‑tezacaftor‑deutivacaftor was non‑inferior to elexacaftor‑tezacaftor‑ivacaftor for FEV1 over 52 weeks, with a comparable safety profile. The regimen simplifies dosing to morning tablets only and supports normalizing CFTR function.
Impact: Demonstrates that a once‑daily CFTR triple modulator can match the current standard regimen, potentially improving adherence and quality of life without sacrificing efficacy.
Clinical Implications: Vanzacaftor‑tezacaftor‑deutivacaftor offers a non‑inferior, once‑daily alternative to ETI for eligible genotypes, supporting regimen simplification in routine CF care.
Key Findings
- Two randomized, double‑blind, active‑controlled phase 3 trials enrolled 398 and 573 participants after a 4‑week ETI run‑in.
- Vanzacaftor‑tezacaftor‑deutivacaftor met non‑inferiority versus ETI for FEV1 change over 52 weeks.
- Safety profiles were broadly comparable between regimens; dosing is once‑daily in the morning for vanzacaftor‑based therapy.
Methodological Strengths
- Double‑blind, randomized, active‑controlled design with 52‑week follow‑up
- Large international enrollment with stratified randomization
Limitations
- Non‑inferiority framework without superiority; details of secondary outcomes not fully specified in abstract
- Generalisability limited to genotypes eligible for CFTR modulation
Future Directions: Head‑to‑head comparisons on patient‑reported outcomes, adherence, and long‑term exacerbation risk; evaluation in broader age ranges and comorbid populations.
BACKGROUND: The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis. Vanzacaftor-tezacaftor-deutivacaftor restored CFTR function in vitro and in phase 2 trials in participants aged 18 years and older resulting in improvements in CFTR function, as measured by sweat chloride concentrations and lung function as measured by spirometry. We aimed to evaluate the efficacy and safety of vanzacaftor-tezacaftor-deutivacaftor compared with standard of care elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older. METHODS: In two randomised, active-controlled, double-blind, phase 3 trials, individuals aged 12 years and older with stable cystic fibrosis with F508del-minimal function (SKYLINE Trial VX20-121-102) or with F508del-F508del, F508del-residual function, F508del-gating, or elexacaftor-tezacaftor-ivacaftor-responsive-non-F508del genotypes (SKYLINE Trial VX20-121-103) were enrolled at 126 and 159 international sites, respectively. Eligible individuals were entered into a 4-week run-in period, during which they received elexacaftor (200 mg once daily), tezacaftor (100 mg once daily), and ivacaftor (150 mg once every 12 h) as two fixed-dose combination tablets in the morning and one ivacaftor tablet in the evening. They were then randomly assigned (1:1) to either elexacaftor (200 mg once daily), tezacaftor (100 mg once daily), and ivacaftor (150 mg once every 12 h) as two fixed-dose combination tablets in the morning and one ivacaftor tablet in the evening, or vanzacaftor (20 mg once daily), tezacaftor (100 mg once daily), and deutivacaftor (250 mg once daily) as two fixed-dose combination tablets in the morning, for the 52-week treatment period. All participants received matching placebo tablets to maintain the treatment blinding. Randomisation was done using an interactive web-response system and stratified by age, FEV FINDINGS: In Trial VX20-121-102 between Sept 14, 2021, and Oct 18, 2022, 488 individuals were screened, of whom 435 entered the 4-week run-in period, and subsequently 398 were randomly assigned and received at least one dose of elexacaftor-tezacaftor-ivacaftor (n=202) or vanzacaftor-tezacaftor-deutivacaftor (n=196). Median age was 31·0 years (IQR 22·6-38·5), 163 (41%) of 398 participants were female, 235 (59%) were male, and 388 (97%) were White. In Trial VX20-121-103, between Oct 27, 2021, and Oct 26, 2022, 699 individuals were screened, of whom 597 entered the 4-week run-in period, and subsequently 573 participants were randomly assigned and received at least one dose of elexacaftor-tezacaftor-ivacaftor (n=289) or vanzacaftor-tezacaftor-deutivacaftor (n=284). Median age was 33·1 years (IQR 24·5-42·2), 280 (49%) of 573 participants were female, 293 (51%) were male, and 532 (93%) were White. The absolute change in least squares mean FEV INTERPRETATION: Vanzacaftor-tezacaftor-deutivacaftor is non-inferior to elexacaftor-tezacaftor-ivacaftor in terms of FEV FUNDING: Vertex Pharmaceuticals.
3. Inflammation-induced Generation of Splenic Erythroblast-like Ter-Cells Inhibits the Progression of Acute Lung Injury via Artemin.
The study identifies a splenic erythroblast‑like cell population (Ter‑cells) arising from megakaryocyte‑erythroid progenitors that limits ALI progression through the neurotrophic factor artemin. This work expands ALI biology beyond leukocytes, implicating distal organ, non‑leukocyte responders as protective modulators.
Impact: Reveals a previously unappreciated spleen–lung axis mediated by erythroblast‑like cells and artemin, opening avenues for cell‑ or factor‑based therapies in ALI/ARDS.
Clinical Implications: Therapeutic augmentation of artemin signaling or harnessing Ter‑cells could represent novel strategies to prevent or attenuate ALI progression, pending translational validation.
Key Findings
- Identification of splenic erythroblast‑like Ter‑cells derived from megakaryocyte‑erythroid progenitors (Ter‑119+ phenotype).
- Ter‑cells mitigate ALI progression via secretion/action of artemin.
- Highlights a protective non‑leukocyte, distal organ cellular response in inflammatory lung injury.
Methodological Strengths
- Mechanistic delineation of a novel protective cell population and effector factor (artemin)
- In vivo relevance in acute lung injury models with cellular and molecular characterization
Limitations
- Preclinical evidence with incomplete mechanistic details in abstract; species translation unknown
- Extent of human relevance and therapeutic window require validation
Future Directions: Define artemin receptor pathways in lung targets, evaluate Ter‑cell/artermin augmentation in diverse ALI etiologies, and explore human correlates.
Identifying inflammation-induced leukocyte subsets and their derived circulating factors has been instrumental in understanding the progression of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Nevertheless, how primary inflammation-induced nonleukocyte populations in distal organs contribute to ALI/ARDS remains poorly defined. Here, we report one population of erythroblast-like cells (Ter-cells) deriving from megakaryocyte-erythroid progenitor cells with a unique Ter-119